methyl 5-(2-methoxyphenyl)-2-methylfuran-3-carboxylate | 1150227-92-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 英文名称: methyl 5-(2-methoxyphenyl)-2-methylfuran-3-carboxylate
• CAS: 1150227-92-1
• 化学式: C₁₄H₁₄O₄
• 分子量: 246.263
• InChiKey: SVCMFGDQFXFDQQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  48.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 5-(2-methoxyphenyl)-2-methylfuran-3-carboxylate 在 水 、 lithium hydroxide 作用下， 以 甲醇 为溶剂， 生成 5-(2-Methoxyphenyl)-2-methylfuran-3-carboxylic acid
  参考文献：
  名称：

  Discovery and hit-to-lead optimization of novel allosteric glucokinase activators

  摘要：

  We report on a hit generation and hit-to-lead program of a novel class of glucokinase activators (GKAs). Hit compounds, activators at low glucose concentration only were identified by vHTS. Scaffold modification reliably afforded activators also at high substrate level. Potency was increased by introduction of a hydrogen bond acceptor as proposed by molecular docking. Replacement of the initial alkylene linkers with a rigid 1,2-phenylene motif followed by further studies eventually furnished a series of potent lead compounds exhibiting steep SAR. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.06.128
• 作为产物：
  描述：

  2-甲基-3-糠酸甲酯 在 N-溴代丁二酰亚胺(NBS) 、 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 methyl 5-(2-methoxyphenyl)-2-methylfuran-3-carboxylate
  参考文献：
  名称：

  Discovery and hit-to-lead optimization of novel allosteric glucokinase activators

  摘要：

  We report on a hit generation and hit-to-lead program of a novel class of glucokinase activators (GKAs). Hit compounds, activators at low glucose concentration only were identified by vHTS. Scaffold modification reliably afforded activators also at high substrate level. Potency was increased by introduction of a hydrogen bond acceptor as proposed by molecular docking. Replacement of the initial alkylene linkers with a rigid 1,2-phenylene motif followed by further studies eventually furnished a series of potent lead compounds exhibiting steep SAR. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.06.128

文献信息

• Heterocyclic compound
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US08309580B2

  公开（公告）日：2012-11-13

  The present invention provides a heterocyclic compound represented by the following formula (I), which has a glucagon antagonistic action and is useful for the prophylaxis or treatment of diabetes and the like, a compound represented by wherein ring A is an optionally substituted benzene ring and the like; Y is a nitrogen atom and the like; X is —O— and the like; R4 is a hydrogen atom and the like; R5 and R6 are each independently a hydrogen atom and the like; R1 is an optionally substituted hydrocarbon group and the like; R2 is a hydrogen atom and the like; and R3 is —(CH2)3—COOH and the like, or a salt thereof.

  本发明提供了一种杂环化合物，其由以下式子（I）表示，具有葡萄糖升高素拮抗作用，用于预防或治疗糖尿病等疾病，其中化合物由以下表示： 其中环A是可选取代的苯环等；Y是氮原子等；X是—O—等；R4是氢原子等；R5和R6各自独立地是氢原子等；R1是可选取代的烃基等；R2是氢原子等；R3是—（CH2）3—COOH等，或其盐。
• HETEROCYCLIC COMPOUND
  申请人：Banno Yoshihiro

  公开号：US20100256156A1

  公开（公告）日：2010-10-07

  The present invention provides a heterocyclic compound represented by the following formula (I), which has a glucagon antagonistic action and is useful for the prophylaxis or treatment of diabetes and the like, a compound represented by wherein ring A is an optionally substituted benzene ring and the like; Y is a nitrogen atom and the like; X is —O— and the like; R 4 is a hydrogen atom and the like; R 5 and R 6 are each independently a hydrogen atom and the like; R 1 is an optionally substituted hydrocarbon group and the like; R 2 is a hydrogen atom and the like; and R 3 is —(CH 2 ) 3 —COOH and the like, or a salt thereof.

  本发明提供了一种由以下式（I）表示的杂环化合物，该化合物具有葡萄糖高升素拮抗作用，并可用于预防或治疗糖尿病等疾病，其中，式中环A为可选取代苯环等；Y为氮原子等；X为—O—等；R4为氢原子等；R5和R6各自独立地为氢原子等；R1为可选取代的碳氢基团等；R2为氢原子等；R3为—（CH2）3—COOH等，或其盐。
• HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2210876B1

  公开（公告）日：2015-05-20
• US8309580B2
  申请人：——

  公开号：US8309580B2

  公开（公告）日：2012-11-13